These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37673115)

  • 1. Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database.
    Bhandari NR; Hess LM; He D; Peterson P
    J Natl Compr Canc Netw; 2023 Sep; 21(9):934-944.e1. PubMed ID: 37673115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data.
    John A; Yang B; Shah R
    Adv Ther; 2021 Mar; 38(3):1552-1566. PubMed ID: 33537872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial versus early switch to targeted therapy during first-line treatment among patients with biomarker-positive advanced or metastatic non-small cell lung cancer in the United States.
    Hess LM; Peterson P; Sugihara T; Bhandari NR; Krein PM; Sireci A
    Cancer Treat Res Commun; 2023; 37():100761. PubMed ID: 37717466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
    Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
    Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
    Sireci AN; Krein PM; Hess LM; Khan T; Willey J; Ayars M; Deyoung K; Bhaskar S; Mumuney G; Coutinho A
    Clin Lung Cancer; 2023 Jul; 24(5):429-436. PubMed ID: 37080814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
    Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
    Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.
    Apple J; Shenolikar R; De Silva K; Sun P; Spira A
    Cancer Med; 2023 Jun; 12(12):13415-13425. PubMed ID: 37306623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics.
    John A; Shah RA; Wong WB; Schneider CE; Alexander M
    Oncologist; 2020 Nov; 25(11):e1743-e1752. PubMed ID: 32627882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
    Pan IW; Mallick R; Dhanda R; Nadler E
    Lung Cancer; 2013 Dec; 82(3):469-76. PubMed ID: 24396885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
    Nadler E; Espirito JL; Pavilack M; Boyd M; Vergara-Silva A; Fernandes A
    Clin Lung Cancer; 2018 Jul; 19(4):360-370. PubMed ID: 29576407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis, testing, treatment, and outcomes among patients with advanced non-small cell lung cancer in the United States.
    Yang M; MacEwan JP; Boppudi SS; McClain MR; O'Hara RM; Paik PK
    Cancer Med; 2023 Dec; 12(24):21605-21614. PubMed ID: 38062905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
    Popat S; Liu SV; Scheuer N; Gupta A; Hsu GG; Ramagopalan SV; Griesinger F; Subbiah V
    JAMA Netw Open; 2022 May; 5(5):e2214046. PubMed ID: 35612853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC.
    Gross CP; Meyer CS; Ogale S; Kent M; Wong WB
    J Natl Compr Canc Netw; 2022 May; 20(5):479-487.e2. PubMed ID: 35545174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.
    Nadler E; Vasudevan A; Wang Y; Ogale S
    Cancer Treat Res Commun; 2022; 31():100522. PubMed ID: 35189530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
    Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
    JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
    Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
    JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
    Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
    Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer.
    Sorial MN; Huynh JP; Azzoli CG; Liauw JC; Brunault RD; Collins CM; Zullo AR
    Eur J Cancer; 2021 Mar; 145():234-244. PubMed ID: 33431285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.